Trial Uncovers That Age Doesn’t Independently Impact Chronic Lymphocytic Leukemia Outcomes

A recent study examined the impact of age on clinical outcomes for patients diagnosed with chronic lymphocytic leukemia (CLL). This study was published in the journal Blood Advances. 

All patients in this trial were treated with a drug called ibrutinib.

The researchers uncovered that age does not independently predict outcomes for this patient population.

Age in CLL

CLL is commonly diagnosed in patients between the ages of 65 and 74. In general, we know that comorbidities and age can predict tolerance of treatment.

The cumulative illness rating scale (CIRS) is used to understand which patients might experience adverse events to treatment based on their demographics and other factors.

Although, compared to other treatments, ibrutinib has demonstrated superior outcomes, adverse outcomes are unfortunately not uncommon.

This trial aimed to evaluate which factors may lead to a higher risk of negative outcomes.

The Study

This study included 712 CLL patients. The average age of participants was 70.1 years, but ages ranged from 40 to 95. This trial was majority male (67.1%). Further, 84.4% of the patients had an Eastern Cooperative Oncology Group performance status score of either 0 or 1. The average CIRS score for patients was 5 but ranged from 0 to 30.

Researchers studied five different outcomes in this investigation. They sought to understand factors which may lead to event free survival (EFS), progression free survival (PFS), overall survival (OS), permanent dose reduction (PDR), and toxicity related discontinuation (Tox-DTD).

Share this post

Share on facebook
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email